Clinical trials: Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
- Trial name
- NCT03955146
- Testing
- Pamrevlumab
- Where
- 125 sites in United States, Argentina and 7 more
- Volunteers
- 393 people
- Sponsor
- Kyntra Bio
Lung Cancer, Sarcoidosis
Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
After randomization, the subjects undergo flexible bronchoscopy either with fractionated propofol administration or with propofol-TCI.
- Conditions
- Lung Cancer, Sarcoidosis, Interstitial Pneumonia
- Trial name
- NCT02246023
- Testing
- Flexible bronchoscopy in moderate sedation, Oxygen saturation, Blood pressure
- Where
- Switzerland
- Volunteers
- 78 people
- Sponsor
- Daniel Franzen
SARS-COv2 Related Interstitial Pneumonia
TOFAcitinib in SARS-CoV2 Pneumonia
Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to SARS-CoV2 infection. Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by blocking IL-6 signal.
- Trial name
- NCT04332042
- Testing
- Tofacitinib
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Università Politecnica delle Marche